COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

30,498 Articles (22,363 medRxiv, 8,135 bioRxiv)

Most recent first Previous |  Page 237: Articles 2361-2370  | Next

Sufficient COVID-19 quarantine and testing on international travelers from China
Bojja, D., Zuo, S., Townsend, J. P.
10.1101/2023.11.03.23297426 — Posted: 2023-11-04
Frequency and determinants of COVID-19 prevention behaviours: assessment of large-scale programmes in seven countries
Bick, S., White, S., Thorseth, A. H., Friedrich, M. N. D., Gavin, I., Gautam, O. P., Dreibelbis, R.
10.1101/2023.11.03.23298032 — Posted: 2023-11-04
Serum Antibody Fingerprinting for SARS-CoV-2 Variants in Infected and Vaccinated Subjects by Label-Free Microarray Biosensor
Carzaniga, T., Casiraghi, L., Nava, G., Zanchetta, G., Inzani, T., Chiari, M., Bollati, V., Epis, S., Bandi, C., Lai, A., Zehender, G., Bellini, T., Buscaglia, M.
10.1101/2023.11.02.23297831 — Posted: 2023-11-03
An exploration into the impact of the COVID-19 pandemic on maternal mental health in high-and middle- income countries with a case study in East Sussex
Ackley, C., Sabesan, A., Stone, S.
10.1101/2023.11.02.23298002 — Posted: 2023-11-03
Forecasting COVID-19 New Cases Using Transformer Deep Learning Model
Patil, S., Mollaei, P., farimani, A. B.
10.1101/2023.11.02.23297976 — Posted: 2023-11-03
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Tamura, T., Mizuma, K., Nasser, H., Deguchi, S., Padilla-Blanco, M., Uriu, K., Tolentino, J. E. M., Tsujino, S., Suzuki, R., Kojima, I., Nao, N., Shimizu, R., Jonathan, M., Kosugi, Y., Guo, Z., Hinay, A. A., Putri, O., Kim, Y., Tanaka, Y. L., Asakura, H., Nagashima, M., Sadamasu, K., Yoshimura, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Saito, A., Ito, J., Irie, T., Zahradnik, J., Ikeda, T., Takayama, K., Matsuno, K., Fukuhara, T., Sato, K.
10.1101/2023.11.02.565304 — Posted: 2023-11-03
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Zhang, L., Xie, X., Luo, H., Yu, H., Huang, J., Shi, P.-Y., Hu, Q.
10.1101/2023.11.01.564972 — Posted: 2023-11-03
Safety and immunogenicity of COReNAPCIN(R), a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial
Salehi, M., Alavi Darazam, I., Nematollahi, A., Alimohammadi, M., Pouya, S., Alimohammadi, R., Khajavirad, N., Porgoo, M., Sedghi, M., Sepahi, M. M., Azimi, M., Hosseini, H. H., Hashemi, S. M., Dehghanizadeh, S., Khoddami, V.
10.1101/2023.11.01.23297898 — Posted: 2023-11-02
Phylogenetic meta-analysis of chronic SARS-CoV-2 infections in immunocompromised patients shows no evidence of elevated evolutionary rates
Oversti, S., Gaul, E., Jensen, B.-E. O., Kuhnert, D.
10.1101/2023.11.01.565087 — Posted: 2023-11-02
Gods Lockdown: the effect of the April 2022 Colorado low blizzard on SARS-Cov-2 transmission in the midwest United States
Strobel, S., Daly, M.
10.1101/2023.11.01.23297908 — Posted: 2023-11-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).